Mekonos, a biotech platform developing cell therapies, has announced a new research collaboration with bit.bio, a synthetic biology company providing human cells for research, drug discovery and cell therapy.
The antibody drug donanemab, developed by the pharma giant Eli Lilly, has met all of its goals in a phase 3 trial for slowing cognitive decline in people with Alzheimer’s disease.
Protein drugs are notoriously difficult to deliver orally – but scientists have developed a new type of oral capsule that could deliver insulin and other similar drugs.
Janssen Biotech has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies....
The US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate (ADC) later this year.
The microbiome therapeutic developer Vedanta Biosciences has raked in $106.5m to bankroll the launch of a phase 3 trial of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI).
The new €350m ($386m) biotechnology research center will help power Boehringer Ingelheim’s development of biopharmaceuticals, which account for around 50% of the company’s research pipeline.
More than a year after imposing a clinical hold on MaaT Pharma’s lead microbiome therapeutic in 2021, the US Food and Drug Administration (FDA) has given clearance for the French firm to begin a phase 3 trial in the US.
Avidity Biosciences, a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1044.
Moderna will explore next generation technologies - including quantum computing and artificial intelligence - to advance and accelerate mRNA research via a new partnership with IBM.
Following a recent phase 2 failure, the San Francisco-based biotech company Nektar Therapeutics has slashed its workforce and axed the development of the protein drug rezpegaldesleukin (Rezpeg) for the treatment of the autoimmune disease systemic lupus...
The radiopharmaceuticals developer Ariceum Therapeutics has bagged $24.9m (€22.8m) in a Series A extension round. Adding to a $27.4m (€25m) Series A closing last year, the Series A winnings for the German startup now total $52.3m (€47.8m).
In a move to increase its presence in immunology and inflammation, the Danish biotech Genmab has launched a collaboration with argenx in the Netherlands to co-discover and co-develop antibody treatments.
The South Korean company is set to create a new facility in West Virginia to house insulin manufacturing and to deliver its insulin products in the country.
An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.
Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.
As part of a $1 billion deal forged in 2020, Biogen has exercised the option to license a treatment candidate for Alzheimer’s disease developed by the US biotech company Denali Therapeutics. The engineered antibody drug is designed to cross into the brain...
Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...
The new study observes a significant association between supplement consumption and vaccination side effects in an Italian adult population, specifically spotlighting the effects of omega-3 and mineral supplement consumption in reducing associated adverse...
Aspect Biosystems and Novo Nordisk have announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics to replace or repair biological functions in the body: with the aim of creating a ‘new class of truly disease-modifying...
A Phase 1 trial found that a freeze-dried, temperature-stable experimental tuberculosis vaccine was safe, well-tolerated and elicited robust antigen-specific serum antibody and Th1-type cellular immune responses.
The biotech startup Immune Bridge has bagged $12 million in a seed financing round to drive the development of natural killer (NK) cells that can be used in cell therapies for cancer.
Moderna has announced new mRNA vaccine development programs: with the Lyme disease candidate representing an expansion of the company's mRNA tech to target bacterial pathogens.
The clinical stage company announces that its potential treatment for relapsed or refractory multiple myeloma receives nod for speedier review by the FDA.
The U.S. biotech Alzamend Neuro has launched a phase 1/2a trial of a therapeutic vaccine for Alzheimer’s disease based on a patient’s immune dendritic cells.
Sensible Biotechnologies will partner with Ginkgo Bioworks to develop an in vivo microbial mRNA manufacturing platform – aiming to address a major bottleneck in mRNA manufacturing.
The company finalizes a deal to establish its first manufacturing facility in Africa, which will have the capacity to produce 500 million vaccine doses per year.
BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets: thus adding ADCs as an additional drug class in BioNTech’s oncology portfolio.
Swiss CDMO Lonza has increased capacity and capabilities at its Visp, Switzerland site, with the completion of a new line for cGMP clinical and commercial drug product manufacturing.
The White House releases a report detailing how it will harness biotechnology and biomanufacturing to address numerous societal challenges, including human health.
Remedium Bio, a US biotech, and Exothera, a Belgian CDMO, have established a collaborative agreement in relation to the US firm’s disease modifying gene therapy for osteoarthritis, AAV2-FGF18.
mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...
BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications....
Oxford UK based Vaccitech reports positive topline interim data from a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
Novartis has presented new data which ‘underscore the transformational and sustained benefit’ of spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec): with treated children maintaining motor milestones after 7.5 years.
Intergalactic Therapeutics, a startup focused on non-viral gene therapy, reports positive preclinical results for its lead program, IG-002, addressing all forms of ABCA4-related retinopathies.
Moderna will expand in the US with new offices in San Francisco and Seattle: while the company also expects to hire around 2,000 new employees globally this year.
The new Clinical Biotechnology Centre (CBC) in Bristol will expand the UK’s ability to make clinical grade products for the research and development of new cell and gene therapies.
OPKO Health’s ModeX Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.
